Search

Nitroprusside

Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency.

Somatrogon

growth hormone caused by growth hormone deficiency, marking Canada as the first country to approve this drug. … It is a chimeric product generated by fusing three copies of the C-terminal peptide (CTP), or 28 carboxy-terminal residues, from the beta chain of human chorionic gonadotropin (hCG) to the N-terminus and

Bortezomib

[A204083] In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. … apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib.

Betibeglogene autotemcel

[L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin. … The use of betibeglogene autotemcel is more effective in patients with β-thalassemia with residual β-globin synthesis (non-β⁰/β⁰ genotype) compared to those with no detectable β-globin

Sutilain

[T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368] … It is able to dissolve the intercellular matrix which helps with desquamation.

Adenosine phosphate

Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937] … Adenosine phosphate, or adenylic acid, is an adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.

Asenapine

Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with … Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.

Pork collagen

The surgical implantation shows a tolerable safety profile and efficacy up to 4 years, but it is not indicated for patients with osteoarthritis. … It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods.

Gallium Ga-68 gozetotide

[L27006] On December 1, 2020, Ga-68 PSMA-11 was approved by the FDA as the first molecular-targeted drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) … [L43542] In December of the same year, the drug was fully authorized by the EMA.[L44682] In Octer 2022, Ga-68 PSMA-11 was approved by Health Canada for diagnostic use in men with prostate cancer.

Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen